跳至主要内容
临床试验/NCT04913909
NCT04913909已完成不适用

Effects of Probiotic Streptococcus Salivarius Strain M18 on Oral Microbiota and Glycemic Control in Patients With Type 2 Diabetes Mellitus; A Randomized Clinical Trial

Istanbul University0 个研究点目标入组 70 人开始时间: 2015年9月10日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
70
主要终点
Change in the Oral Microbiota colony counts at baseline and after intervention

研究概览

简要总结

The present study evaluated clinically the effects of a probiotic on oral microbiota and glycemic control in T2 diabetic patients with periodontal disease. The study was designed as a prospective randomized, double-blind, placebo- controlled interventional study. At baseline and at the end of the 30 day- probiotic period, all clinical, microbiological, and biochemical measurements were tested. Colony counts of oral microbiota, blood fructosamine levels and CRP were the outcomes of the study.

详细描述

Objectives: To investigate the effects of an oral probiotic use, containing 4 billion colony forming unit (CFU/g) Streptococcus Salivarius M18 strain (Dentoblis™), on the quantities of oral microbiota in saliva and metabolic markers of T2 diabetics such as fructosamine, C-reactive protein (CRP).

Materials and Methods

The trial was designed as a prospective randomized, double-blind, placebo- controlled interventional study. Participants were selected from type 2 diabetics with periodontitis and aged 30-65 years, who presented to the Diabetic Center in Istanbul. Totally 70 patients were randomly assigned to probiotic or placebo groups. At baseline and at the end of the 30 day-probiotic period, colony counts of oral microbiota and biochemical measurements of diabetes were assessed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

Neither the investigators nor the subjects were aware of the contents of the lozenges except for the research nurse, who was also responsible for keeping the codes and information confidential until after the statistical calculations. Statistical analysis were performed by a blind assessor.

入排标准

年龄范围
30 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • being diagnosed with T2 diabetes with <10% HbA1C for at least 6 months,
  • 30-65 years old patients,
  • high caries activity patients with Periodontal Disease Index (PDI) scores of 2, 3, 4 and 5,
  • provision of written informed consent -

排除标准

  • patients regularly using probiotics,
  • patients on corticosteroid, non-steroid anti-inflammatory, antibiotic or antibacterial mouthwash therapy,
  • patients with multi-organ deficiency such as liver or kidney failure,
  • patients with Immunodeficiency syndrome or on immunosuppressive therapy,
  • patients with heart valve prosthesis or central venous catheter,
  • patients undergoing chronic or acute disease therapy such as cancer, arthritis, influenza, flu,
  • legal incapability or mental incapacity to give consent.

结局指标

主要结局

Change in the Oral Microbiota colony counts at baseline and after intervention

时间窗: 30 days

Colony counts of periodontal pathogens, S.mutans and candidas were determined 30 day after the use of the Probiotic in CFU/g

Change in blood fructosamine levels in Type 2 diabetic patients an Oral probiotic use

时间窗: 30 days

Clinical marker of Type 2 diabetics such as CRP and fructosamine were determined 30 day after the use of the Probiotic

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Murat Tokgoz,DDS,DrPH

Researcher

Istanbul University

相似试验